5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft

Bone Marrow Transplantation
J SteinmannM Lübbert

Abstract

DNA-hypomethylating agents are a viable treatment option for AML/myelodysplastic syndrome (MDS) relapse after allograft by upregulating Ags on blasts before DLI. Seventy-two patients with relapsed AML (n=62), MDS (n=8) and other myeloid neoplasms (n=2) after allograft were treated with low-dose 5-azacytidine and, if feasible, DLI. median age 62 years (range 20-75), 42% with adverse cytogenetics, 82% not in remission at transplant and 83% received fludarabine-based reduced-toxicity conditioning. Median duration from transplant to 5-azacytidine was 289 days (range 59-2133). Response criteria: CR, temporary disease control or treatment failure. A median of 2.7 courses (range 1-10) were administered; 65 out of 72 patients also received DLI (41 already before 5-azacytidine). Ten patients developed acute GVHD and two succumbed to treatment-related sepsis. CR rate was 9.7% (in two patients lasting >5 years), 44% had temporary disease control (median duration 71 days, range 31-380). Median survival from 5-azacytidine was 108 days, 21 patients proceeded to subsequent transplant. In multivariate analysis, peripheral blood blasts <1% were predictive of longer OS (P=0.03). Taken together, long-term remissions can be induced by this well-to...Continue Reading

References

Apr 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hartmut BertzJürgen Finke
Aug 13, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dimitri A BreemsBob Löwenberg
Feb 26, 2013·British Journal of Haematology·Christine L PhillipsJohn P Perentesis

❮ Previous
Next ❯

Citations

Jul 1, 2015·Experimental Hematology·Clémence LoiseauRaphael Itzykson
Mar 31, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ibraheem H MotabiJohn F DiPersio
May 25, 2016·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Luca CastagnaLucio Morabito
Oct 19, 2016·Leukemia Research Reports·Michael MedingerJakob Passweg
Nov 29, 2016·European Journal of Haematology·Christina RautenbergThomas Schroeder
Dec 29, 2016·Experimental Hematology·Guillermo OrtiDavid Valcarcel
Jan 11, 2018·British Journal of Haematology·Armin RashidiNelli Bejanyan
Jan 11, 2019·Leukemia & Lymphoma·Hongbing MaYuping Gong
Nov 17, 2017·International Journal of Hematology·Thomas SchroederGuido Kobbe
Dec 7, 2019·British Journal of Haematology·Arnab GhoshMiguel-Angel Perales
Sep 13, 2019·Expert Opinion on Investigational Drugs·Georgina S Daher-ReyesKaren W L Yee
Feb 27, 2020·Japanese Journal of Clinical Oncology·Kittika PoonsombudlertNath Limpruttidham
Jul 6, 2016·Journal of Hematology & Oncology·Gilles FransoletFrédéric Baron
Mar 25, 2019·Current Oncology Reports·Maximilian Stahl, Aaron D Goldberg
Nov 5, 2019·Frontiers in Cell and Developmental Biology·Valentina GambacortaRaffaella Di Micco
Jan 13, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christoph SchmidGesine Bug
Mar 30, 2021·Hematology/oncology and Stem Cell Therapy·Amany R KeruakousCarrie Yuen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.